Factors influencing the health-related quality of life in Hungarian multiple sclerosis patients

Füvesi, Judit; Bencsik, Krisztina; Losonczi, Erika; Fricska-Nagy, Zs.; Mátyás, Klotild; Mészáros, Eszter; Benedek, Krisztina; Rajda, Cecília; Lencsés, Gy.; Vécsei, László

doi:10.1016/j.jns.2010.03.007

Cited by 16 publications

(14 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite growing interest in the impact of comorbidity on outcomes in MS, 5,90 and the emergence of therapies that increase the risk of comorbidity or that may be relatively contraindicated in the presence of comorbidity, 273 relatively little high-quality information is available regarding the incidence or prevalence of comorbidity in MS at any point in the disease course. Future work should develop and validate population-based data sources for surveillance of comorbidity worldwide.…”

Section: Discussionmentioning

confidence: 99%

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

et al. 2015

View full text Add to dashboard Cite

Background:Comorbidity is an area of increasing interest in multiple sclerosis (MS).Objective:The objective of this review is to estimate the incidence and prevalence of comorbidity in people with MS and assess the quality of included studies.Methods:We searched the PubMed, SCOPUS, EMBASE and Web of Knowledge databases, conference proceedings, and reference lists of retrieved articles. Two reviewers independently screened abstracts. One reviewer abstracted data using a standardized form and the abstraction was verified by a second reviewer. We assessed study quality using a standardized approach. We quantitatively assessed population-based studies using the I2 statistic, and conducted random-effects meta-analyses.Results:We included 249 articles. Study designs were variable with respect to source populations, case definitions, methods of ascertainment and approaches to reporting findings. Prevalence was reported more frequently than incidence; estimates for prevalence and incidence varied substantially for all conditions. Heterogeneity was high.Conclusion:This review highlights substantial gaps in the epidemiological knowledge of comorbidity in MS worldwide. Little is known about comorbidity in Central or South America, Asia or Africa. Findings in North America and Europe are inconsistent. Future studies should report age-, sex- and ethnicity-specific estimates of incidence and prevalence, and standardize findings to a common population.

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Though a strong, negative correlation was determined between depression scale and life satisfaction, depression and hopelessness scores were not correlated. The literature suggests that quality of life deteriorats in patients with MS and a high level of depression is connected to the lower quality of life (29,30). Moreover, there is a consensus on the association between hopelessness and depression in MS (18,19).…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, there is a consensus on the association between hopelessness and depression in MS (18,19). Füvesi et al indicated that the quality of life in MS deteriorates moderately and that there is a negative correlation between depression and quality of life (30). Similarly, Janardhan & Bakshi concluded that along with depression, physical disability including fatigue was associated with impaired quality of life in MS (31).…”

Section: Discussionmentioning

confidence: 99%

Multipl Skleroz Hastalarinda Umutsuzluk, Depresyon Ve Yaşam Doyumu

Aşiret¹,

Özdemir²,

Maraşlıoğlu³

2014

tnd

View full text Add to dashboard Cite

Objective: This study was carried out to determine the level of hopelessness, depression, and life satisfaction among patients with multiple sclerosis. Ma te ri al and Met hod:Sixty-five patients with multiple sclerosis, treated at the neurology clinic of a university hospital, were included in this study. In this descriptive study, a data collection form developed by the researchers, the Beck Depression Scale, and the Beck Hopelessness and Life Satisfaction Scale were used.Re sults: Almost half (43.1%) of the patients exhibited severe depressive symptoms. Patients' hopelessness and life satisfaction levels were moderate. The scores on depression and life satisfaction scales were correlated negatively. While patients' traits including female gender, low economic level, difficulties in walking, and fatigue were associated with reduced life satisfaction; variables such as having a child, low economic and education levels, experiencing incontinence, and fatigue were related to a higher level of depressive symptoms. Conclusion:The majority of patients were depressed; life satisfaction and hopelessness levels were moderate. Linear regression analysis revealed that education and emotional problems determined 42% of the depression score; and economic level and emotional problems identified 32% of the life satisfaction score. ÖzetAmaç: Bu çalışma multipl skleroz (MS) hastalarının umutsuzluk, depresyon ve yaşam doyumu düzeyini belirlemek amacıyla yapılmıştır.Ge reç ve Yön tem: Çalışmaya, bir üniversite hastanesinin nöroloji kliniğinde tedavi gören 65 MS hastası alınmıştır. Bu tanımlayıcı çalışmada, araştırmacılar tarafından geliştirilen veri toplama formu, Beck Depresyon ve Beck Umutsuzluk ve Yaşam Doyumu Ölçekleri kullanılmıştır. Bulgular:Hastaların yarıya yakını (%43,1) ciddi depresif semptomlar göstermektedir. Hastaların umutsuzluk ve yaşam doyumu düzeyleri ortadır. Depresyon ve yaşam doyumu ölçek skorları ters ilişkilidir. Kadın cinsiyet, düşük ekonomik düzey, yürümede zorluk ve yorgunluk gibi hasta özellikleri bozulmuş yaşam doyumuna eşlik ederken çocuk sahibi olma, düşük ekonomik ve eğitim düzeyi, inkontinans ve yorgunluk deneyimleme gibi değişkenler yüksek düzeyde depresif semptomlarla ilişkilidir.Sonuç: Hastaların çoğunluğu depresyondadır; yaşam doyumu ve umutsuzluk düzeyleri ortadır. Linear regresyon analizi, eğitim ve duygusal problemin depresyon ölçeği skorunu %42 oranında, ekonomik düzey ve duygusal problemin ise yaşam doyumunu %32 oranında belirlediğini göstermiştir. (Türk Nöroloji Dergisi 2014; 20:1-6) Anah tar Ke li me ler: Multipl Skleroz, depresyon, yaşam doyumu, hemşirelik

show abstract

“…Multiple sclerosis (MS) is the most common demyelinating disorder of the central nervous system that usually affects young adults . The disease is characterized by multifocal, inflammatory, and immune‐mediated central nervous system injury, which can cause a variety of symptoms and consequently requires comprehensive medical care .…”

mentioning

confidence: 99%

Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis

Mokhber

Azarpazhooh

Orouji

et al. 2015

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

Aims:The aim of this study was to evaluate the effect of various disease-modifying therapies (DMT) on quality of life in multiple sclerosis (MS).Methods: This was a three-arm parallel study with balanced randomization in which 90 newly diagnosed, definite MS subjects referred to Ghaem Medical Center, Mashhad, Iran were enrolled between 2006 and 2009. Patients were randomly allocated into three DMT groups: Avonex, Rebif and Betaferon. Health-related quality of life was assessed in MS patients at baseline and 12 months after treatment with DMT using the MS Quality of Life-54 questionnaire.Results: Both mental and physical health scores improved within all three treatment groups after 12 months of treatment; however, this increase was only significant in the mental health composite in the Betaferon group (P = 0.024). Betaferon had the highest mental health score change (14.04) while this change was 7.26 for Avonex (P = 0.031) and 5.08 for Rebif (P = 0.017). A physical health composite score comparison among the three treatment groups revealed no significant results. Conclusions:With a positive impact of DMT on mental and physical dimensions of QOL in MS patients, initiation of treatment soon after diagnosis is recommended. In MS patients with more mental issues and fewer physical disabilities, Betaferon might be considered as a better choice of treatment.Key words: disease-modifying therapies, multiple sclerosis, quality of life. M ULTIPLE SCLEROSIS (MS) is the most common demyelinating disorder of the central nervous system that usually affects young adults.1 The disease is characterized by multifocal, inflammatory, and immune-mediated central nervous system injury, which can cause a variety of symptoms and consequently requires comprehensive medical care. [2][3][4] MS, as a long-term illness, can result not only in physical disabilities, but also in substantial mental health problems influencing the quality of life (QOL) of patients, their partners, families, and caregivers. 5-7The health-related QOL, or the capacity to derive satisfaction from meaningful behavior despite disease, is a topic of increasing interest to clinicians caring for MS patients. Hence in patients with MS, apart from complete psychophysical and objective neurologic status, a subjective perception of signs and symptoms, known as QOL, needs to be considered. Disease-modifying therapies (DMT) have a beneficial effect on the course of MS in terms of reducing the relapse rates and delaying the onset and progression of disabilities. [12][13][14][15][16][17] In spite of limited data on QOL and its correlation with DMT, it is possible that DMT influence the QOL, independent of the physical disabilities.18 As treatment with β-interferon (IFN-β) is a life-long treatment and patients often experience various side-effects, a positive effect on the patient's QOL is critical. [12][13][14]19 Therefore, this study investigates the effect of DMT (IFN-β-1a [Avonex and Rebif] and IFN-β-1b [Betaferon]) on QOL in a group of MS patients. METHODS Study designThe c...

show abstract

Factors influencing the health-related quality of life in Hungarian multiple sclerosis patients

Cited by 16 publications

References 26 publications

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview

Multipl Skleroz Hastalarinda Umutsuzluk, Depresyon Ve Yaşam Doyumu

Therapeutic effect of Avonex, Rebif and Betaferon on quality of life in multiple sclerosis

Contact Info

Product

Resources

About